SCOPUS 정보 검색 플랫폼

Volumn 48, Issue 1, 2013, Pages 47-55

Rapamycin increases neuroblastoma xenograft and host stromal derived osteoprotegerin inhibiting osteolytic bone disease in a bone metastasis model

(8) Hartwich, Joseph E a,c Orr, W Shannon b,c Ng, Catherine Y c Spence, Yunyu c McLaughlin, Jillian M c Furman, Wayne L c McGregor, Lisa M c Davidoff, Andrew M b,c

a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE (United States)

b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER (United States)

c ST JUDE CHILDREN S RESEARCH HOSPITAL (United States)

Author keywords

Bone metastasis; Neuroblastoma; Osteoprotegerin; Rapamycin

Indexed keywords

OSTEOPROTEGERIN; RAPAMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE ATROPHY; BONE METASTASIS; BONE RADIOGRAPHY; CANCER MODEL; CELL PROLIFERATION; COCULTURE; CONTROLLED STUDY; CORTICAL BONE; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IN VITRO STUDY; MESENCHYMAL STEM CELL; MOUSE; NEUROBLASTOMA; NEUROBLASTOMA CELL; NONHUMAN; OSTEOCLASTOGENESIS; PATHOLOGIC FRACTURE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR XENOGRAFT; UPREGULATION;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOLOGICAL MARKERS; BONE NEOPLASMS; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FRACTURES, SPONTANEOUS; HUMANS; INJECTIONS, INTRAPERITONEAL; MICE; MICE, SCID; NEUROBLASTOMA; OSTEOPROTEGERIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIROLIMUS; TREATMENT OUTCOME;

EID: 84872385073 PISSN: 00223468 EISSN: 15315037 Source Type: Journal
DOI: 10.1016/j.jpedsurg.2012.10.043 Document Type: Article

Times cited : (9)

References (14)

1
- 0031911489
- Multivariate analysis of risk factors in stage 4 neuroblastoma patients over the age of one year treated with megatherapy and stem-cell transplantation: A report from the European Bone Marrow Transplantation Solid Tumor Registry
- R. Ladenstein, T. Phillip, and C. Lasset Multivariate analysis of risk factors in stage 4 neuroblastoma patients over the age of one year treated with megatherapy and stem-cell transplantation: a report from the European Bone Marrow Transplantation Solid Tumor Registry J Clin Oncology 16 3 1998 953 965
- (1998) J Clin Oncology , vol.16 , Issue.3 , pp. 953-965
- Ladenstein, R.¹ Phillip, T.² Lasset, C.³

2
- 58149391059
- Outcome of high-risk stage 3 neuroblastoma with myeloablative therapy and 13-cis retinoic acid: A report from the Children's Oncology Group
- J.R. Park, J.G. Villablanca, and W.B. London Outcome of high-risk stage 3 neuroblastoma with myeloablative therapy and 13-cis retinoic acid: a report from the Children's Oncology Group Pediatr Blood Cancer 52 2009 44 50
- (2009) Pediatr Blood Cancer , vol.52 , pp. 44-50
- Park, J.R.¹ Villablanca, J.G.² London, W.B.³

3
- 4444257291
- RANKL/RANK/OPG: New therapeutic targets in bone tumors and associated osteolysis
- Y. Wittrant, S. Theoleyre, and C. Chipoy RANKL/RANK/OPG: new therapeutic targets in bone tumors and associated osteolysis Biochem Biophys Acta 1704 2004 49 57
- (2004) Biochem Biophys Acta , vol.1704 , pp. 49-57
- Wittrant, Y.¹ Theoleyre, S.² Chipoy, C.³

4
- 0035866399
- Receptor activator of nuclear factor κb ligand (RANKL) is a key molecule of osteoclast formation for bone metastasis in a newly developed model of human neuroblastoma
- T. Michigami, M. Ihara-Watanabe, and M. Yamazaki Receptor activator of nuclear factor κB ligand (RANKL) is a key molecule of osteoclast formation for bone metastasis in a newly developed model of human neuroblastoma Cancer Res 61 2001 1637 1644
- (2001) Cancer Res , vol.61 , pp. 1637-1644
- Michigami, T.¹ Ihara-Watanabe, M.² Yamazaki, M.³

5
- 72849114497
- Denosumab: The era of targeted therapies in bone metastatic diseases
- D. Santini, M.E. Fratto, and B. Vincenzi Denosumab: the era of targeted therapies in bone metastatic diseases Curr Cancer Drug Targets 9 2009 834 842
- (2009) Curr Cancer Drug Targets , vol.9 , pp. 834-842
- Santini, D.¹ Fratto, M.E.² Vincenzi, B.³

6
- 4143057125
- In Vitro blockade of receptor activator of nuclear factor-κB ligand prevents osteoclastogenesis induced by neuroblastoma cells
- D. Granchi, I. Amato, and L. Battistelli In Vitro blockade of receptor activator of nuclear factor-κB ligand prevents osteoclastogenesis induced by neuroblastoma cells Int J Cancer 111 2004 829 838
- (2004) Int J Cancer , vol.111 , pp. 829-838
- Granchi, D.¹ Amato, I.² Battistelli, L.³

7
- 0346837985
- A phase i study of AMGN-0007 a recombinant osteoprotegerin construct in patients with multiple myeloma or breast carcinoma related bone metastases
- J.J. Body, P. Greipp, and R.E. Coleman A phase I study of AMGN-0007 a recombinant osteoprotegerin construct in patients with multiple myeloma or breast carcinoma related bone metastases Cancer 97 3 Suppl 2003 887 892
- (2003) Cancer , vol.97 , Issue.3 SUPPL , pp. 887-892
- Body, J.J.¹ Greipp, P.² Coleman, R.E.³

8
- 58149514116
- Neural progenitor-cell mediated delivery of osteoprotegerin limits disease progression in a preclinical model of neuroblastoma bone metastasis
- T.L. Sims, J.B. Hamner, and R.A. Bush Neural progenitor-cell mediated delivery of osteoprotegerin limits disease progression in a preclinical model of neuroblastoma bone metastasis J Pediatr Surg 44 2009 204 211
- (2009) J Pediatr Surg , vol.44 , pp. 204-211
- Sims, T.L.¹ Hamner, J.B.² Bush, R.A.³

9
- 40449091406
- Initial testing (stage I) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program
- P.J. Houghton, C.L. Morton, and E.A. Kolb Initial testing (stage I) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program Pediatr Blood Cancer 50 2008 799 805
- (2008) Pediatr Blood Cancer , vol.50 , pp. 799-805
- Houghton, P.J.¹ Morton, C.L.² Kolb, E.A.³

10
- 46249094677
- Rapamycin affects early fracture healing in mice
- J.H. Holstein, M. Klein, and P. Garcia Rapamycin affects early fracture healing in mice Brit J Pharm 154 2008 1055 1062
- (2008) Brit J Pharm , vol.154 , pp. 1055-1062
- Holstein, J.H.¹ Klein, M.² Garcia, P.³

11
- 65549101998
- Down-regulation of mTOR leads to up-regulation of osteoprotegerin in bone marrow cells
- M. Mogi, and A. Kondo Down-regulation of mTOR leads to up-regulation of osteoprotegerin in bone marrow cells Biochem Biophys Rsch Comm 384 2009 82 86
- (2009) Biochem Biophys Rsch Comm , vol.384 , pp. 82-86
- Mogi, M.¹ Kondo, A.²

12
- 34347360705
- In vivo bioluminescence imaging for early detection and monitoring of disease in a murine model of neuroblastoma
- P.V. Dickson, B. Hamner, and C.Y. Ng In vivo bioluminescence imaging for early detection and monitoring of disease in a murine model of neuroblastoma J Pediatr Surg 42 2007 1172 1179
- (2007) J Pediatr Surg , vol.42 , pp. 1172-1179
- Dickson, P.V.¹ Hamner, B.² Ng, C.Y.³

13
- 0037015049
- Novel adenoassociated viruses from rhesus monkeys as vectors for human gene therapy
- G.P. Gao, M.R. Alvira, and L. Wang Novel adenoassociated viruses from rhesus monkeys as vectors for human gene therapy Proc Natl Acad Sci USA 99 2002 11854 11859
- (2002) Proc Natl Acad Sci USA , vol.99 , pp. 11854-11859
- Gao, G.P.¹ Alvira, M.R.² Wang, L.³

14
- 33746783759
- Efficacy of zoledronate against neuroblastoma
- P.V. Dickson, J.B. Hamner, and L.A. Cauthen Efficacy of zoledronate against neuroblastoma Surgery 140 2 2006 227 235
- (2006) Surgery , vol.140 , Issue.2 , pp. 227-235
- Dickson, P.V.¹ Hamner, J.B.² Cauthen, L.A.³

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.